333 related articles for article (PubMed ID: 28188101)
1. Antiangiogenic Therapy in Advanced Non-small-cell Lung Cancer: A Meta-analysis of Phase III Randomized Trials.
Raphael J; Chan K; Karim S; Kerbel R; Lam H; Santos KD; Saluja R; Verma S
Clin Lung Cancer; 2017 Jul; 18(4):345-353.e5. PubMed ID: 28188101
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of chemotherapy or tyrosine kinase inhibitors combined with bevacizumab versus chemotherapy or tyrosine kinase inhibitors alone in the treatment of non-small cell lung cancer: a systematic review and meta-analysis.
Sun L; Ma JT; Zhang SL; Zou HW; Han CB
Med Oncol; 2015 Feb; 32(2):473. PubMed ID: 25603953
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness and safety of bevacizumab for unresectable non-small-cell lung cancer: a meta-analysis.
Yang K; Wang YJ; Chen XR; Chen HN
Clin Drug Investig; 2010; 30(4):229-41. PubMed ID: 20225906
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of combining targeted therapy with pemetrexed or docetaxel as second-line treatment in patients with advanced non-small-cell lung cancer: a meta-analysis of 14 randomized controlled trials.
Li X; Wang H; Lin W; Xu Q
Curr Med Res Opin; 2014 Nov; 30(11):2295-304. PubMed ID: 24701984
[TBL] [Abstract][Full Text] [Related]
5. Antiangiogenic agents combined with chemotherapy in the first-line treatment of advanced non-small-cell lung cancer: overall and histology subgroup-specific meta-analysis.
Zhang L; Cao F; Wang Y; Wang S; Zhong D
Oncol Res Treat; 2014; 37(12):710-8. PubMed ID: 25531716
[TBL] [Abstract][Full Text] [Related]
6. The addition of anti-angiogenic tyrosine kinase inhibitors to chemotherapy for patients with advanced non-small-cell lung cancers: A meta-analysis of randomized trials.
Li BT; Barnes TA; Chan DL; Naidoo J; Lee A; Khasraw M; Marx GM; Kris MG; Clarke SJ; Drilon A; Rudin CM; Pavlakis N
Lung Cancer; 2016 Dec; 102():21-27. PubMed ID: 27987583
[TBL] [Abstract][Full Text] [Related]
7. Comparative effectiveness of combined therapy inhibiting EGFR and VEGF pathways in patients with advanced non-small-cell lung cancer: a meta-analysis of 16 phase II/III randomized trials.
Zhao Y; Wang H; Shi Y; Cai S; Wu T; Yan G; Cheng S; Cui K; Xi Y; Qi X; Zhang J; Ma W
Oncotarget; 2017 Jan; 8(4):7014-7024. PubMed ID: 27690345
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Antigen-specific Immunotherapy in the Treatment of Patients with Non-small-cell Lung Cancer: A Systematic Review and Meta-analysis.
Yan BD; Cong XF; Zhao SS; Ren M; Liu ZL; Li Z; Chen C; Yang L
Curr Cancer Drug Targets; 2019; 19(3):199-209. PubMed ID: 29714142
[TBL] [Abstract][Full Text] [Related]
9. Erlotinib-based targeted dual agent versus erlotinib alone in previously treated advanced non-small-cell lung cancer: a meta-analysis of 13 randomized controlled trials.
Yu S; Xu Q; Yuan Y; Li X; Cai H
Curr Med Res Opin; 2016 Dec; 32(12):1927-1934. PubMed ID: 27479336
[TBL] [Abstract][Full Text] [Related]
10. Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with immune checkpoint inhibitors: A systematic review and meta-analysis.
Chen R; Hou X; Yang L; Zhao D
Thorac Cancer; 2019 Apr; 10(4):607-623. PubMed ID: 30734504
[TBL] [Abstract][Full Text] [Related]
11. The Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer Harboring Wild-type Epidermal Growth Factor Receptor: A Meta-analysis of 25 RCTs.
Sheng Z; Zhang Y
Am J Clin Oncol; 2017 Aug; 40(4):362-369. PubMed ID: 25647830
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of angiogenesis inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis.
Hong S; Tan M; Wang S; Luo S; Chen Y; Zhang L
J Cancer Res Clin Oncol; 2015 May; 141(5):909-21. PubMed ID: 25373315
[TBL] [Abstract][Full Text] [Related]
13. The role of bevacizumab in solid tumours: A literature based meta-analysis of randomised trials.
Roviello G; Bachelot T; Hudis CA; Curigliano G; Reynolds AR; Petrioli R; Generali D
Eur J Cancer; 2017 Apr; 75():245-258. PubMed ID: 28242502
[TBL] [Abstract][Full Text] [Related]
14. The role of angiogenesis inhibitors in the treatment of elderly patients with advanced non-small-cell lung cancer: A meta-analysis of eleven randomized controlled trials.
Tian RH; Wu X; Liu X; Yang JW; Ji HL; Yan YJ
J Cancer Res Ther; 2016; 12(2):571-5. PubMed ID: 27461612
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of Addition of Antiangiogenic Agents to Taxanes-Containing Chemotherapy in Advanced Nonsmall-Cell Lung Cancer: A Meta-Analysis and Systemic Review.
Sheng J; Yang YP; Yang BJ; Zhao YY; Ma YX; Hong SD; Zhang YX; Zhao HY; Huang Y; Zhang L
Medicine (Baltimore); 2015 Aug; 94(31):e1282. PubMed ID: 26252298
[TBL] [Abstract][Full Text] [Related]
16. Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer.
Soria JC; Mauguen A; Reck M; Sandler AB; Saijo N; Johnson DH; Burcoveanu D; Fukuoka M; Besse B; Pignon JP;
Ann Oncol; 2013 Jan; 24(1):20-30. PubMed ID: 23180113
[TBL] [Abstract][Full Text] [Related]
17. Magnitude of the benefit of progression-free survival as a potential surrogate marker in phase 3 trials assessing targeted agents in molecularly selected patients with advanced non-small cell lung cancer: systematic review.
Hotta K; Kato Y; Leighl N; Takigawa N; Gaafar RM; Kayatani H; Hirata T; Ohashi K; Kubo T; Tabata M; Tanimoto M; Kiura K
PLoS One; 2015; 10(3):e0121211. PubMed ID: 25775395
[TBL] [Abstract][Full Text] [Related]
18. Biomarker analyses from a randomized, placebo-controlled, phase IIIb trial comparing bevacizumab with or without erlotinib as maintenance therapy for the treatment of advanced non-small-cell lung cancer (ATLAS).
Kabbinavar F; Fehrenbacher L; Hainsworth J; Kasubhai S; Kressel B; Marsland T; Patel T; Rubin M; White L; Yang JC; Klughammer B; Colburn D; Miller V; Johnson BE
J Thorac Oncol; 2014 Sep; 9(9):1411-7. PubMed ID: 25122437
[TBL] [Abstract][Full Text] [Related]
19. Dual inhibiting EGFR and VEGF pathways versus EGFR-TKIs alone in the treatment of advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials.
Zhang TT; Wang RM; Yang Z; Chen GB
Clin Transl Oncol; 2016 Jun; 18(6):576-81. PubMed ID: 26527033
[TBL] [Abstract][Full Text] [Related]
20. Indirect comparison between pembrolizumab and nivolumab for the treatment of non-small cell lung cancer: A meta-analysis of randomized clinical trials.
Peng TR; Tsai FP; Wu TW
Int Immunopharmacol; 2017 Aug; 49():85-94. PubMed ID: 28554108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
